Latest Period
Q1 2026
Security Snapshot
KIORA PHARMACEUTICALS INC - Common Stock, $0.01 par value (KPRX) Institutional Ownership
CUSIP: 49721T507
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
18
Shares (Excl. Options)
339,203
Price
$1.93
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.01 par value
- Symbol
- KPRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 339,203
- Total 13F value
- $654,660
- Portfolio coverage rank
- 0%
- Share change
- -367,742
- Value change
- -$727,610
- Number of holders
- 18
- Shares outstanding
- 4,389,079
- SEC-reported price per share
- $2.69
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KPRX - KIORA PHARMACEUTICALS INC - Common Stock, $0.01 par value is tracked under CUSIP 49721T507.
- 18 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 19 to 18 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,392,679 to $654,660.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 18 institutions filings for Q1 2026.
Security key
49721T507
Latest holder period
Q1 2026
13F holders
18
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
KPRX full holder history
KIORA PHARMACEUTICALS INC SEC filings
KIORA PHARMACEUTICALS INC company facts
KIORA PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 49721T507:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
KPRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 10% | 0% | $947,093 | +$161,475 | 438,469 | +21% | Nantahala Capital Management, LLC | 31 Mar 2026 |
| Alyeska Investment Group, L.P. | 10% | +250% | $852,483 | +$689,126 | 394,668 | +422% | Alyeska Investment Group, L.P. | 31 Mar 2026 |
| ADAR1 Capital Management, LLC | 9.9% | $1,095,537 | 365,179 | ADAR1 Capital Management GP, LLC | 30 Jun 2025 | |||
| HIRSCHMAN ORIN | 4.9% | -40% | $380,178 | -$123,265 | 192,984 | -24% | Orin Hirschman | 31 Dec 2025 |
| Nantahala Capital Partners Limited Partnership | 3.4% | -38% | $321,270 | -$88,493 | 148,736 | -22% | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 31 Mar 2026 |
| GOLDMAN SACHS GROUP INC | 0% | $429 | 130 | THE GOLDMAN SACHS GROUP, INC. | 31 Dec 2024 |
As of 31 Mar 2026, 18 institutional investors reported holding 339,203 shares of KIORA PHARMACEUTICALS INC - Common Stock, $0.01 par value (KPRX). This represents 7.7% of the company’s total 4,389,079 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 339,203 | $654,660 | -$727,610 | $1.93 | 18 |
| 2025 Q4 | 706,945 | $1,392,679 | +$165,896 | $1.97 | 19 |
| 2025 Q3 | 616,169 | $1,714,712 | -$910,084 | $2.78 | 17 |
| 2025 Q2 | 931,843 | $2,683,707 | -$1,054,952 | $2.88 | 16 |
| 2025 Q1 | 1,285,403 | $3,869,063 | +$78,079 | $3.01 | 18 |
| 2024 Q4 | 1,259,459 | $4,164,082 | +$76,847 | $3.30 | 16 |
| 2024 Q3 | 1,213,569 | $4,441,661 | +$905,961 | $3.66 | 18 |
| 2024 Q2 | 966,044 | $4,057,360 | +$4,057,360 | $4.20 | 15 |